Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

4.480 -0.180 (-3.86%)
Streaming Delayed Price Updated: 1:58 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Top movers in Thursday's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics
Via Benzinga
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Y-mAbs Therapeutics Stock
Via Benzinga
Examining the Future: Y-mAbs Therapeutics's Earnings Outlook
Via Benzinga
Navigating 8 Analyst Ratings For Y-mAbs Therapeutics
Via Benzinga
Earnings Scheduled For March 4, 2025
Via Benzinga
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Assessing Y-mAbs Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
The company didn't quite meet expectations for either trailing results or full-year guidance. 
Via The Motley Fool
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Outlook For Y-mAbs Therapeutics
Via Benzinga
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
Micro Marvel - Y-Mabs Therapeutics
Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.